Valuation: Immuneering Corporation

Market Cap 267M 232M 216M 199M 375M 25.47B 382M 2.56B 1B 12.7B 1B 981M 42.04B P/E 2026 *
-3.75x
P/E 2027 * -3.24x
Enterprise Value 267M 232M 216M 199M 375M 25.47B 382M 2.56B 1B 12.7B 1B 981M 42.04B EV / Sales 2026 *
-
EV / Sales 2027 * 13.7x
Free-Float
86.18%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immuneering Corporation

1 day+0.97%
1 week-3.47%
Current month+0.97%
1 month-19.65%
3 months-22.35%
6 months-13.49%
Current year-36.63%
1 week 4.03
Extreme 4.03
4.36
1 month 4.03
Extreme 4.03
5.7
Current year 3.86
Extreme 3.86
8.48
1 year 2.9
Extreme 2.9
10.08
3 years 1
Extreme 1
10.88
5 years 1
Extreme 1
33.99
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 01/02/2008
Director of Finance/CFO 61 16/07/2026
Chief Tech/Sci/R&D Officer - 01/08/2023
Director TitleAgeSince
Chairman 81 01/01/2008
Director/Board Member 44 01/02/2008
Director/Board Member 72 27/04/2021
Date Insider Type Main position Quantity % Market Cap.
7/16/26 A Other

Chief Financial Officer

225,000 0.3478%
7/16/26 A Free

Chief Financial Officer

650,000 1.0047%
2/3/26 A Free

Chief Technology Officer

140,000 0.2168%
Change 5-day change 1-year change 3-year change Capi.($)
+0.97%-3.47%+23.74%-60.96% 267M
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-10.22%+23.62%+58.59% 53.6B
+1.84%+3.27%-14.06%-12.13% 22.91B
-0.15%-7.92%-9.42%+352.23% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-1.73%+33.09%-31.09% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+3.83%-0.56%+47.77%+170.70% 13.33B
Average +1.14%-2.13%+37.32%+142.93% 23.41B
Weighted average by Cap. +0.14%-1.70%+31.71%+122.92%

Financials

2026 *2027 *
Net sales - 19.5M 16.94M 15.8M 14.52M 27.39M 1.86B 27.86M 186M 72.99M 927M 73.23M 71.61M 3.07B
Net income -74.87M -65.06M -60.65M -55.75M -105M -7.14B -107M -716M -280M -3.56B -281M -275M -11.78B -87.34M -75.89M -70.75M -65.03M -123M -8.33B -125M -835M -327M -4.15B -328M -321M -13.74B
Net Debt - -
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
55
Date Price Change Volume
03/08/26 $4.170 +0.97% 497,361
31/07/26 $4.130 -2.36% 409,671
30/07/26 $4.230 +4.32% 510,073
29/07/26 $4.055 -4.36% 801,355
28/07/26 $4.240 -2.75% 712,595
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.130USD
Average target price
18.86USD
Spread / Average Target
+356.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMRX Stock